[EN] INDOLE-2 -CARBOXAMIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE INDOLE-2 -CARBOXAMIDINE UTILISES COMME ANTAGONISTES DU RECEPTEUR NMDA
申请人:RICHTER GEDEON VEGYESZET
公开号:WO2006010965A1
公开(公告)日:2006-02-02
The present invention relates therefore first to new indole-2-carboxamidine derivatives of formula (I) - wherein the meaning of X is hydrogen or halogen atom, C1-C4 alkyl, C1-C4 alkoxy, trifluoromethyl group, Y, V and Z independently are hydrogen or halogen atom, hydroxy, cyano, C1-C4 alkylsulfonamido optionally substituted by a halogen atom or halogen atoms, C1-C4 alkanoylamido optionally substituted by a halogen atom or halogen atoms, trifluoromethyl, trifluoromethoxy, C1-C4 alkyl, C1-C4 alkoxy group, or the neighboring V and Z groups in given case together with one or more identical or different additional hetero atom and -CH= and/or -CH2- groups can form an optionally substituted 4-7 membered homo- or heterocyclic ring, preferably benzene, dioxolane ring, A, B and C independently are substituted carbon atom or one of them is nitrogen atom, and the salts thereof. Further objects of the invention are the processes for producing indole-2-carboxamidine derivatives of formula (I), and the pharmaceutical manufacture of medicaments containing these compounds, as well as the process of treatments with these compounds, which means administering to a mammal to be treated - including human - effective amount/amounts of indole-2-carboxamidine derivatives of formula (I) of the present invention as such or as medicament. The new indole-2-carboxamidine derivatives of formula (I) of the present invention are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.
本发明首先涉及新的吲哚-2-羧酰胺衍生物,其化学式为(I),其中X的含义为氢原子或卤素原子,C1-C4烷基,C1-C4烷氧基,三氟甲基基团,Y、V和Z独立地为氢原子或卤素原子,羟基,氰基,C1-C4烷基磺酰胺基可选择地被卤素原子或卤素原子取代,C1-C4烷酰胺基可选择地被卤素原子或卤素原子取代,三氟甲基,三氟甲氧基,C1-C4烷基,C1-C4烷氧基,或在特定情况下与一个或多个相同或不同的额外杂原子和-CH=和/或-CH2-基团一起形成可选择取代的4-7元杂环或杂环,优选为苯环,二氧兰环,A、B和C独立地为取代的碳原子或其中之一为氮原子,以及其盐。本发明的进一步目标是制备化学式(I)的吲哚-2-羧酰胺衍生物的工艺,以及含有这些化合物的药物的制造,以及使用这些化合物进行治疗的过程,即向待治疗的哺乳动物(包括人类)施用本发明的吲哚-2-羧酰胺衍生物的有效量/量,作为药物或本身。本发明的新吲哚-2-羧酰胺衍生物化学式(I)是NMDA受体高效选择性拮抗剂,而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。